Valcon Medical II

Direct 

• Offering of safe, effective and quality medicines for health-care and human well-being: Valcon Medical manufactures medicinal cannabis products that enhance human well-being, providing alternative treatments for chronic pain, epilepsy, and other conditions where conventional medicines may fail Their products improve symptom management and reduce dependence on addictive opioids. 
  Medical cannabis treats conditions like chronic pain, multiple sclerosis (MS), epilepsy, Spinal cord injury and cancer-related symptoms. It is an option for patients who experience a lack of efficacy or poor tolerance to conventional medicine, and often complements current medication for managing pain, muscle spasms, seizures, and nausea.  
• Promotion of innovation and entrepreneurship: a relevant portion of the funding is dedicated to developing a new product format for the European medical cannabis market – a medical cannabis vaporization and inhalation devices, which provide rapid relief for breakthrough pain. Valcon Medical will invest in advanced extraction technologies to improve the efficiency and yield of cannabis extracts, ensuring that the extracts maintain high potency and purity, crucial for medical applications. By being one of the first to introduce medical cannabis inhalation products in Europe, Valcon Medical positions itself as an industry innovator, setting a benchmark for others and driving industry progress. 

Indirect 

• Implementation of sustainable practices of consumption and production: Valcon Medical, certified by the ISO 14001 for environmental management systems (EMS), implements a strategy for environmental sustainability at the company’s activities level and similar can be found at their supplier. The company uses energy from Danish renewable sources and, in the production, implements efficient extraction technologies that reduce resources consumption and waste. The promoter prioritizes the use of environmentally friendly solvents in extraction processes which are less harmful to the environment and contribute to safer working conditions.  At their primary supplier, Schroll Medical, they implement sustainable agricultural practices: reduced or no synthetic pesticides and fertilizers; efficient water use with efficient techniques like drip irrigation and water recycling in the cultivation; energy efficiency through LED lighting and use of renewable energy from their own solar system; crop rotation and composting; biodegradable and recyclable packaging materials; and prioritization of local suppliers.  
• Promotion of community awareness and advocacy: Valcon Medical is actively involved in policy advocacy to shape effective public policies and access regarding medical cannabis in Denmark and across Europe. Also, the company invests in community outreach programs to educate the public about the benefits and safe use of medical cannabis. 
• Creation of jobs: with this funding for the company’s growth, Valcon Medical foresees hiring 10 people during the loan’s two years as permanent positions medical production professionals and regulatory specialists.

Valcon Medical A/S, establecida en 2018 y con sede en el área metropolitana de Copenhague, en Dinamarca, es una organización de producción farmacéutica con certificación GMP especializada en la extracción y elaboración de cannabis medicinal.

El uso del cannabis medicinal tiene un impacto profundo en los pacientes, y a muchos de ellos les alivia el dolor crónico, la epilepsia y otras condiciones debilitantes. Además, la adopción del cannabis medicinal está contribuyendo a reducir el consumo de opiáceos, ya que es una opción más segura para el tratamiento del dolor y la lucha contra la crisis de los opiáceos que ha asolado muchas regiones. Este movimiento progresista marca un importante paso adelante en la atención sanitaria y el bienestar de los pacientes en toda Europa.

Como proveedor líder de extractos de cannabis medicinal en Europa, Valcon Medical está a la vanguardia de esta transformación. La empresa suministra elaboraciones terapéuticas extraídas del cannabis medicinal a mercados farmacéuticos de toda Europa, incluidos los de Alemania, Dinamarca, Reino Unido y Polonia. En Dinamarca, Valcon Medical ofrece una gama de productos que se adaptan a las necesidades locales de los pacientes bajo la marca de Valcon, ScanLeaf. Valcon Medical cuenta en su cartera de productos diversas elaboraciones de aceite estandarizadas y el primer producto de inhalación de cannabis medicinal de Alemania de acción rápida para el alivio del dolor.

Valcon Medical opera bajo un claro enfoque en la calidad, la consistencia y la escalabilidad. El equipo directivo de la empresa está compuesto por profesionales con amplia experiencia en los campos farmacéutico, biotecnológico, financiero y regulatorio. Valcon Medial cuenta con la certificación GMP desde 2021 y con productos validados según los estándares de la Farmacopea Europea, y está bien posicionada para satisfacer la creciente demanda de cannabis medicinal en Europa. Su filial, Scanleaf, proporciona acceso único al mercado escandinavo, lo que garantiza una distribución directa y eficiente de sus productos.